Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pacira BioSciences, Inc. - Common Stock (NQ:PCRX)

26.21 +0.31 (+1.20%)
Streaming Delayed Price Updated: 11:08 AM EDT, Sep 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 65,782
Open 26.01
Bid (Size) 26.17 (200)
Ask (Size) 26.23 (200)
Prev. Close 25.90
Today's Range 25.98 - 26.41
52wk Range 18.80 - 27.66
Shares Outstanding 44,454,792
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Pacira Biosciences (NASDAQ:PCRX): A Value Play with Fundamentals Intact ↗
Via Chartmill
News headline image
Pacira (PCRX) Q2 2026 Earnings Call Transcript ↗
EXPAREL revenue grew 3% while company divested iovera and expanded insurance coverage. 
Via The Motley Fool
Topics Earnings

Performance

YTD
+7.2%
+7.2%
1 Month
-2.6%
-2.6%
3 Month
+14.2%
+14.2%
6 Month
+23.2%
+23.2%
1 Year
-3.7%
-3.7%

More News

Read More
News headline image
Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
Pacira Biosciences (NASDAQ:PCRX) Beats Q2 EPS Estimates, Misses on Revenue and Cuts Outlook ↗
Via Chartmill
Pacira Biosciences Inc (NASDAQ:PCRX) Emerges as a Deep Value Opportunity with Strong Financial Health ↗
Via Chartmill
PACIRA BIOSCIENCES INC (NASDAQ:PCRX): A Value Stock Candidate with Margin of Safety ↗
Via Chartmill
News headline image
Pacira BioSciences Reports Second Quarter 2026 Financial Results
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Announces New National Survey Revealing the Hidden Toll of Pain on America’s Workforce
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Process
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL®
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer Biomet
From Pacira BioSciences
Via GlobeNewswire
News headline image
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Pacira’s Director Nominees
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Mails Letter to Stockholders Reiterating Confidence in the Company’s Strategic Direction and Highly Qualified Nominees
From Pacira BioSciences
Via GlobeNewswire
News headline image
After Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast Instead
From Biotech Insider
Via GlobeNewswire
News headline image
Pacira BioSciences Reports Real-World Study Showing EXPAREL® Use Was Associated with Reduced Opioid Use and Healthcare Costs in Patients Undergoing Total Shoulder Arthroplasty
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Sets the Record Straight Regarding DOMA’s Misleading Statements About Pacira’s Intellectual Property Strategy
From Pacira BioSciences
Via GlobeNewswire
News headline image
A Reno Biotech Just Rang the Nasdaq Bell — Here’s Why the Whole Regenerative-Medicine Tape Is Worth Watching
From World Street Intelligence
Via GlobeNewswire
News headline image
Pacira BioSciences Files Investor Presentation Highlighting Successful Execution of its Long-Term Strategy to Drive Value for All Stockholders
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences to Participate in Fireside Chats at Three Upcoming Healthcare Conferences
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Mails Letter to Stockholders
From Pacira BioSciences
Via GlobeNewswire

Frequently Asked Questions

Is Pacira BioSciences, Inc. - Common Stock publicly traded?
Yes, Pacira BioSciences, Inc. - Common Stock is publicly traded.
What exchange does Pacira BioSciences, Inc. - Common Stock trade on?
Pacira BioSciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Pacira BioSciences, Inc. - Common Stock?
The ticker symbol for Pacira BioSciences, Inc. - Common Stock is PCRX on the Nasdaq Stock Market
What is the current price of Pacira BioSciences, Inc. - Common Stock?
The current price of Pacira BioSciences, Inc. - Common Stock is 26.21
When was Pacira BioSciences, Inc. - Common Stock last traded?
The last trade of Pacira BioSciences, Inc. - Common Stock was at 09/01/26 11:08 AM ET
What is the market capitalization of Pacira BioSciences, Inc. - Common Stock?
The market capitalization of Pacira BioSciences, Inc. - Common Stock is 1.17B
How many shares of Pacira BioSciences, Inc. - Common Stock are outstanding?
Pacira BioSciences, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.